CurrentFidelis CarePolicy N/A

Gastric Electrical Stimulation (GES) — Coverage Criteria

Medical necessity and coding guidance for gastric electrical stimulation (GES) for treatment of diabetic and idiopathic gastroparesis for members/enrollees of the Health Plan; describes required clinical criteria, device/regulatory considerations, and related procedure codes.

Policy Summary

PayerFidelis Care

PolicyGastric Electrical Stimulation (GES) — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateJan 25, 2025

Key ActionObtain prior authorization and document age ≥18, confirmed diabetic or idiopathic gastroparesis by gastric emptying scintigraphy, failed trials of antiemetic/dietary/prokinetic therapy, and chronic drug-refractory nausea and vomiting.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

diabetic & idiopathiceligible gastroparesis types

≥18minimum age

HDEdevice regulatory pathway

CPT/HCPCS/L-codescodes referenced

Coverage Criteria for Gastric Electrical Stimulation

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Therapy

GES is medically necessary when ALL of the following are met:

Eligibility criteria set

Age: Member/enrollee is ≥ 18 years of age.>= 18 years
Diagnosis confirmation: Diagnosis of diabetic or idiopathic gastroparesis confirmed by gastric emptying scintigraphy.
Conservative therapy failure: Documented intolerance or failure of trial of antiemetic therapy, dietary modifications, and prokinetic drug therapy (recommended prokinetic options include metoclopramide and erythromycin).
Symptoms: Chronic intractable (drug-refractory) nausea and vomiting.
Pregnancy: Not currently pregnant.
Regulatory compliance: Device and use are in accordance with FDA Humanitarian Device Exemption (HDE) specifications.

Not Medically Necessary / Not Supported Indications

Unsupported indications: Use of GES for reduction of pain, fullness, bloating, acid reflux, obesity, or other indications not listed above is not supported by current evidence and is considered not medically necessary.

GES is not supported for indications other than diabetic or idiopathic gastroparesis. Current evidence does not support use of gastric electrical stimulation for other conditions, including but not limited to treatment of obesity.

GES is considered not medically necessary for the purpose of reducing symptoms of pain, fullness, bloating, or acid reflux, as there is no evidence to support efficacy of GES for these symptom indications.

Procedure and Device Codes

Procedure and supply CPT/HCPCS codesmixed

43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.
43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open.
43882	Revision or removal of gastric neurostimulator electrodes, antrum, open.
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64595	Revision or removal of peripheral, sacral, or gastric neurostimulator generator or receiver, with detachable connection to electrode pulse array.
95980	Electronic analysis of implanted neurostimulator generator system; intraoperative, with programming.
95981	Electronic analysis of implanted neurostimulator generator system; subsequent, without reprogramming.
95982	Electronic analysis of implanted neurostimulator generator system; subsequent, with reprogramming.
C1767	Generator, neurostimulator (implantable) non-rechargeable.

1–10 of 11

1/2

HCPCS L-codes for neurostimulator devicesHCPCS

L8679	Implantable neurostimulator, pulse generator; any type.
L8680	Implantable neurostimulator electrode, each.
L8685	Implantable neurostimulator generator; single array, rechargeable, includes extension.
L8686	Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension.
L8687	Implantable neurostimulator generator, dual array, rechargeable, includes extension.
L8688	Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension.

Provider Requirements and Prior Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required for implantation, revision, removal, programming, and related device services for gastric electrical stimulation (GES). Submit prior authorization requests with the required clinical documentation listed below to allow review for medical necessity.

Affected CPT/HCPCS: 43647, 43648, 43881, 43882, 64590, 64595, 95980-95982; HCPCS: L8679, L8680, L8685-L8688; C-codes: C1767, C1778
Prior auth required for: implantation, replacement, revision, removal, intraoperative and subsequent programming/electronic analysis, and device supply codes
Ensure device is provided per FDA HDE specifications and IRB approval when applicable

Documentation Required

Conservative Therapy Requirement

Documented conservative therapy trial and failure/intolerance are required prior to consideration of GES for diabetic or idiopathic gastroparesis. Evidence of inadequate response to antiemetic therapy, dietary modifications, and prokinetic drug therapy must be included in the prior authorization submission.

Document trial and intolerance or failure of antiemetic therapy (e.g., ondansetron, promethazine) and symptom modulators when used
Document dietary modification attempts (e.g., small frequent meals, low-fat, liquid nutritional strategies) and outcomes
Document trial of recommended combination prokinetic therapy (e.g., metoclopramide and erythromycin) and response
Note use of centrally acting antidepressants when used as symptom modulators

Documentation Required

Required Documentation for Medical Necessity

Complete clinical documentation must be submitted to support medical necessity of GES. Incomplete or missing documentation may result in denial of the request.

Member age (must be ≥ 18 years)
Definitive diagnosis: diabetic or idiopathic gastroparesis confirmed by gastric emptying scintigraphy (include study report and results)
Clinical history of chronic intractable (drug-refractory) nausea and vomiting with duration and severity
Documentation of trials and failures/intolerance of antiemetic therapy, dietary modifications, and prokinetic therapy (see conservative therapy items)
Medication history including doses, durations, and response to metoclopramide, erythromycin, and other agents
Evidence device will be provided and used in accordance with FDA Humanitarian Device Exemption (HDE) specifications and IRB approval where required
Pregnancy status (must not be currently pregnant)
Operative and device-related plans including proposed CPT/HCPCS/C-code billing as applicable
Relevant prior procedures, comorbidities, and life expectancy considerations

Denial Risk

Unsupported Indications — Denial Risk

GES for indications other than diabetic or idiopathic gastroparesis is not supported by current evidence and may be denied. This includes use for reduction of pain, fullness, bloating, acid reflux, obesity, or other off-label conditions without strong evidence.

Requests for GES to treat pain, fullness, bloating, or gastroesophageal reflux will generally be denied
GES for indications outside diabetic or idiopathic gastroparesis (including obesity) is considered unsupported and may be denied

Clinical Background

Gastroparesis is characterized by delayed gastric emptying without mechanical obstruction and commonly presents with nausea, vomiting, early satiety, bloating, and abdominal discomfort. Severe disease can lead to weight loss, dehydration, electrolyte disturbances, and malnutrition. Gastric electrical stimulation (GES) is an implanted therapy intended primarily to reduce refractory nausea and vomiting in patients who have failed conventional treatments; it is used as compassionate care in select, drug-refractory cases and has shown improvements in nausea, vomiting, and quality of life measures though it does not consistently normalize gastric emptying.

Definitions and Regulatory Context

Gastric Electrical Stimulation (GES) — device description and implantation overview

System componentsLeads are placed in the muscularis propria of the greater curvature of the stomach (~10 cm proximal to the pylorus) and connected to a subcutaneous pulse generator typically implanted in the right or left upper abdominal quadrant.

FunctionGenerator delivers programmed electrical stimulation intended to reduce symptoms (primarily nausea and vomiting) of gastroparesis; external programmer controls stimulation parameters.

Mechanism and clinical effectsStimulation has not consistently improved gastric emptying but has been associated with reduced nausea and vomiting and improved quality-of-life measures; proposed mechanisms include modulation of gastric pacemaker activity and afferent pathways.

Indication contextUsed as compassionate care for patients refractory to conventional treatment and as an alternative to more invasive surgery for symptom reduction in gastroparesis.

Implantation overviewLeads are surgically implanted into the gastric muscularis propria and tunneled to a subcutaneous pocket where the generator is placed; intraoperative and subsequent device programming/analysis codes apply.

Humanitarian Use Device / HDE — regulatory explanation and IRB/consent requirements

Regulatory pathwayGES devices referenced in this policy are approved under the FDA Humanitarian Device Exemption (HDE)/Humanitarian Use Device (HUD) pathway for conditions affecting fewer than 8,000 individuals annually.

IRB / local committee requirementA HUD may only be used in facilities that have an established institutional review board (IRB) to supervise clinical testing and after an IRB or appropriate local committee has approved use to treat or diagnose the specific disease.

Use limitations tied to HDEDevice use must comply with HDE specifications as a condition of medical necessity per the policy (see coverage criteria requiring HDE compliance).

Documentation noteProviders should note HDE compliance in clinical documentation and ensure local IRB/committee approval when applicable.